Global Cardiovascular Drugs Market
By Disease Type (Hypertension, Congestive Heart disease, Angina pectoris, Myocardial Ischemia, Peripheral Artery Diseases, Atherosclerosis, Cardiomyopathy, Others), By Drug Class (Anti-hypertensive Drugs, Lipid lowering drugs, Beta-adrenergic Blocking Agents, Vasodilators, Anti-platelet Agents, Others), By Route of Administration (Oral, Buccal/sublingual, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2016 and Forecast 2017-2024
Market Outline: Cardiovascular Drugs Market
Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases.
Market Dynamics: Cardiovascular Drugs Market
Increase in the prevalence of cardiovascular diseases, for instance, according to World health organization 2015, approximately 17.7 Mn people died from cardiovascular diseases around the globe, rise in R&D activities for the innovation of newer cardiovascular drugs, government support to increase the awareness about the cardiovascular diseases and treatment are anticipated to fuel the cardiovascular drugs market. Moreover, change in lifestyle, promising product pipeline, rise in prevalence of obesity, and wider access to cardiovascular drugs in the market are anticipated to propel the market. However, stringent regulatory guidelines for the product approval, high cost of treatment, and adverse effects associated with the medications are hampering the growth of cardiovascular drugs market.
Market Scope: Cardiovascular Drugs Market
Global Cardiovascular drugs market is segmented on the basis of indication, drug class, route of administration, distribution channel, and region
Based on the indication, the market is segmented into the following:
- Hypertension
- Congestive Heart disease
- Angina pectoris
- Myocardial Ischemia
- Peripheral Artery Diseases
- Atherosclerosis
- Cardiomyopathy
- Others
Based on the drug class, the market is segmented into the following:
- Calcium Channel Blockers
- Angiotensin Converting Enzyme (ACE) inhibitors
- Angiotensin-II Receptor antagonists
- Diuretics
- Lipid-lowering drugs
- Beta-adrenergic Blocking Agents
- Vasodilators
- Anti-platelet Agents
- Others
Based on the route of administration, the market is segmented into the following:
- Oral
- Buccal/sublingual
- Intravenous
- Oral
- Others
Based on distribution channel, the market is segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on region, the market is segmented into the following:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Summary: Cardiovascular Drugs Market
Global cardiovascular drugs market has tremendous growth rate over the forecast years owing to increase in the prevalence of various cardiovascular diseases and rise in R&D activities for the innovation of newer drugs. According to World Health Organization 2015, approximately 17.7 Mn deaths occured due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for the R&D activities, and patent expiration of blockbuster are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of cardiovascular drugs market. For instance, in November 2015, AstraZeneca acquired ZS Pharma to strengthen its cardiovascular drugs portfolio by developing novel treatment for hyperkalemia, typically associated with chronic heart failure (CHF). In addition, in June 2016, Espero Pharmaceuticals received FDA approval for Gonitro (Nitroglycerin) sublingual powder used for acute relief of an angina pectoris attack due to coronary artery disease.
Regional Analysis: Cardiovascular Drugs Market
Geographically, global cardiovascular drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America cardiovascular drugs market accounted for significant share owing to increase in the prevalence of cardiovascular diseases (according to centers for Disease Control and Prevention, approximately 610,000 deaths occur due to various heart diseases in U.S. every year) and rise in R&D activities in North America region. Europe cardiovascular drugs market exhibiting lucrative growth due to increase in incidences of cardiovascular diseases majorly in Germany, Russia, UK, Ukraine, and Italy. Asia Pacific cardiovascular drugs market is growing at notable rate due to increase in geriatric population in India, China, and Japan, rise in medical tourism in Asia Pacific countries, and government support for the prevention of cardiovascular diseases in various countries. Latin America cardiovascular drugs market has significant growth which is attributed to increase in prevalence of cardiovascular diseases in Chile, Argentina, and Brazil. Middle East and Africa cardiovascular drugs market is growing due to expansion of business by market players, rise in prevalence of cardiovascular diseases, and government support to protect the public health.
Competition Assessment: Cardiovascular Drugs Market
Some of the players in the global cardiovascular drugs market include:
- AstraZeneca plc (U.K.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bristol Myers Squibb (U.S.)
- Pfizer, Inc. (U.S.)
- Sanofi S.A. (France)
- Boehringer Ingelheim GmbH (Germany)
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Espero Pharmaceuticals, Inc. (U.S.)
Notable Market Developments: Cardiovascular Drugs Market
- In February 2017, Pfizer, Inc. and Washington University collaborated to develop newer drugs in certain therapeutic areas include cardiovascular diseases
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2013 to 2016) and forecast (2017 to 2024)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
